Pieris Pharmaceuticals Current Ratio 2014-2021 | PIRS

Pieris Pharmaceuticals current ratio from 2014 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Pieris Pharmaceuticals Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.13B $0.04B 2.91
2021-03-31 $0.09B $0.03B 2.92
2020-12-31 $0.08B $0.02B 3.42
2020-09-30 $0.09B $0.02B 4.50
2020-06-30 $0.09B $0.02B 5.04
2020-03-31 $0.10B $0.02B 4.80
2019-12-31 $0.12B $0.03B 4.26
2019-09-30 $0.10B $0.04B 2.46
2019-06-30 $0.11B $0.04B 2.72
2019-03-31 $0.12B $0.04B 3.02
2018-12-31 $0.14B $0.05B 2.82
2018-09-30 $0.15B $0.04B 3.62
2018-06-30 $0.16B $0.05B 2.99
2018-03-31 $0.17B $0.06B 3.03
2017-12-31 $0.09B $0.05B 1.96
2017-09-30 $0.10B $0.04B 2.44
2017-06-30 $0.10B $0.04B 2.87
2017-03-31 $0.06B $0.01B 5.13
2016-12-31 $0.03B $0.01B 3.90
2016-09-30 $0.04B $0.01B 4.13
2016-06-30 $0.04B $0.01B 6.84
2016-03-31 $0.04B $0.01B 5.37
2015-12-31 $0.03B $0.00B 11.32
2015-09-30 $0.03B $0.00B 15.23
2015-06-30 $0.01B $0.00B 4.18
2015-03-31 $0.02B $0.00B 6.65
2014-12-31 $0.02B $0.00B 5.63
2014-09-30 $0.00B 0.00
2014-06-30 $0.00B 0.00
2014-03-31 $0.00B 0.00
2013-12-31 $0.01B $0.00B 2.74
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.304B $0.029B
Pieris Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's drug technology consists of Anticalin(R) to treat cancer, severe asthma, anemia and other medical conditions. Pieris Pharmaceuticals, Inc. is based in Freising-Weihenstephan, Germany.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $129.416B 8.62
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.526B 21.21
Biohaven Pharmaceutical Holding (BHVN) United States $9.249B 0.00
Emergent Biosolutions (EBS) United States $2.705B 6.53
Arcus Biosciences (RCUS) United States $2.404B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.873B 0.00
Myovant Sciences (MYOV) United Kingdom $1.831B 0.00
Zymeworks (ZYME) Canada $1.080B 0.00
Ambrx Biopharma (AMAM) United States $0.464B 0.00
SQZ Biotechnologies (SQZ) United States $0.372B 0.00
Enzo Biochem (ENZ) United States $0.161B 15.86